To include your compound in the COVID-19 Resource Center, submit it here.

Anthera discontinues development of Sollpura

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) discontinued development of Sollpura liprotamase (LY3031642) after the candidate missed the primary endpoint in the Phase III RESULT trial to treat exocrine

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE